User login
Key clinical point: Ultra-deep sequencing identified genetic mutations of the BCR/ABL1 tyrosine kinase domain in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) receiving nilotinib that could have prognostic implications in predicting molecular response (MR) duration.
Major finding: V299 L mutation associated with dasatinib resistance and nilotinib sensitivity was observed in 98% of patients. Of all the detected mutations, only V371A mutation vs. no mutation was associated with shorter sustained major MR for 2 years (75% vs. 100%; P = .039) and sustained MR 4.5 for 15 months (25.0% vs. 94.1%; P = .002).
Study details: Findings are from a prospective analysis of 50 patients with newly diagnosed Ph+ CML-CP undergoing first-line nilotinib therapy.
Disclosures: This study was funded by Novartis Pharmaceuticals Corporation. The authors declared no conflict of interests.
Source: Park H et al. Leuk Res. 2021;111:106728 (Oct 15).Doi: 10.1016/j.leukres.2021.106728.
Key clinical point: Ultra-deep sequencing identified genetic mutations of the BCR/ABL1 tyrosine kinase domain in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) receiving nilotinib that could have prognostic implications in predicting molecular response (MR) duration.
Major finding: V299 L mutation associated with dasatinib resistance and nilotinib sensitivity was observed in 98% of patients. Of all the detected mutations, only V371A mutation vs. no mutation was associated with shorter sustained major MR for 2 years (75% vs. 100%; P = .039) and sustained MR 4.5 for 15 months (25.0% vs. 94.1%; P = .002).
Study details: Findings are from a prospective analysis of 50 patients with newly diagnosed Ph+ CML-CP undergoing first-line nilotinib therapy.
Disclosures: This study was funded by Novartis Pharmaceuticals Corporation. The authors declared no conflict of interests.
Source: Park H et al. Leuk Res. 2021;111:106728 (Oct 15).Doi: 10.1016/j.leukres.2021.106728.
Key clinical point: Ultra-deep sequencing identified genetic mutations of the BCR/ABL1 tyrosine kinase domain in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) receiving nilotinib that could have prognostic implications in predicting molecular response (MR) duration.
Major finding: V299 L mutation associated with dasatinib resistance and nilotinib sensitivity was observed in 98% of patients. Of all the detected mutations, only V371A mutation vs. no mutation was associated with shorter sustained major MR for 2 years (75% vs. 100%; P = .039) and sustained MR 4.5 for 15 months (25.0% vs. 94.1%; P = .002).
Study details: Findings are from a prospective analysis of 50 patients with newly diagnosed Ph+ CML-CP undergoing first-line nilotinib therapy.
Disclosures: This study was funded by Novartis Pharmaceuticals Corporation. The authors declared no conflict of interests.
Source: Park H et al. Leuk Res. 2021;111:106728 (Oct 15).Doi: 10.1016/j.leukres.2021.106728.